MIST
Milestone Pharmaceuticals In
NASDAQ · Pharmaceuticals
$1.76
+0.04 (+2.33%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.43M | 19.07M | 23.97M |
| Net Income | 7.18M | 5.86M | 8.22M |
| EPS | — | — | — |
| Profit Margin | 33.5% | 30.7% | 34.3% |
| Rev Growth | +15.6% | +19.4% | -5.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 52.13M | 58.80M | 47.90M |
| Total Equity | 101.36M | 104.63M | 96.86M |
| D/E Ratio | 0.51 | 0.56 | 0.49 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 12.24M | 12.52M | 14.11M |
| Free Cash Flow | 4.04M | 4.46M | 4.28M |